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Transcatheter mitral interventions has been developed to address an unmet clinical need and may be an alternative therapeutic option to surgery
with the intent to provide symptomatic and prognostic benefit. Beyond MitraClip therapy, alternative repair technologies are being developed to
expand the transcatheter intervention armamentarium. Recently, the feasibility of transcatheter mitral valve implantation in native non-calcified
valves has been reported in very high-risk patients. Acknowledging the lack of scientific evidence to date, it is difficult to predict what the ultimate
future role of transcatheter mitral valve interventions will be. The purpose of the present report is to review the current state-of-the-art of mitral
valve intervention, and to identify the potential future scenarios, which might benefit most from the transcatheter repair and replacement devices
under development.
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Introduction
Mitral regurgitation (MR) affects almost 10% of individuals over 75
years of age.1 Open-heart surgery is the gold standard for the treat-
ment of severe MR as excellent outcomes can be achieved in most
patients, often adopting minimally invasive approaches. However,
in up to 50% of patients with severe MR surgical treatment is not per-
formed owing to increased risk related to comorbidities.2 Transcath-
eter mitral interventions may be an alternative therapeutic option,3,4
Transcatheter edge-to-edge repair with the MitraClip system
(Abbott Vascular Inc, Menlo Park, CA, USA) has demonstrated
safety and efficacy in different clinical settings.3,4 Additional repair
and replacement technologies are being developed to expand the
transcatheter intervention armamentarium (Tables 1 and 2).5 Trans-
catheter mitral valve implantation (TMVI) with transcatheter aortic
valve implantation (TAVI) prostheses has been performed in patients
with surgical degenerated bioprostheses or with recurrent MR fol-
lowing annuloplasty.6,7 Recently, few cases of TAVI prostheses
implanted in a calcified native valve have been reported.8,9 The feasi-
bilityof TMVI in native non-calcifiedvalveshasbeen recently reported
in very high-risk patients, mainly with functional MR (FMR).10
Acknowledging the lack of scientific evidence to date, it is difficult
to predict what the ultimate future role of transcatheter mitral valve
interventions will be. The purpose of the present report is to review
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Table 1 Transcatheter mitral valve repair technology under development
Device name and therapy
type
Device structure Status international Description
MitraClip (Abbot Vascular)
Edge-to-edge repair
CE Mark approval
gained
FDA approved
– Percutaneous mitral repair based on Alfieri edge-to-edge surgical
approach, designed for both degenerative and FMR.
– Features a tiny V-shaped clip.
– Indication requested for FDA approval is significant symptomatic
DMR in presence of prohibitive risk for mitral valve surgery
NeoChord (NeoChord
DS1000)
Chordal repair
CE Mark approval
gained
– Instrumentation used to enable beating heart, transapical
approach, mitral valve repair by artificial chordae implantation
– Designed for leaflet prolapse
V-Chordal-Off Pump (Valtech)
Chordal repair
First-in-man study
complete
– Sutureless implantation of neochordae on the leaflets under
direct surgical exposure
– Off-pump, the chordal length can be adjusted under live echo
guidance, on beating heart
CARILLON (Cardiac
Dimensions)
Indirect Annuloplasty
CE Mark approval
gained
IDE submitted for
pivotal study
– Implantable mitral annular constraint device percutaneously
placed into the coronary sinus and great cardiac vein
– Constructed of nitinol wire with distal and proximal anchors
connected by an intervening cable
– Designed specifically for heart failure patients with significant MR
due to mitral annular enlargement
GDS Accucinch (GDS)
Direct Annuloplasty
International feasibility
trial underway
– Catheter-based delivery of a sub-valvular left ventricualr
reshaping (ventriculoplasty) system designed to reshape and
resize the left ventricular base
– Re-establish native mitral valve geometry while preserving native
leaflet function, and restore leaflet coaptation
Mitralign Bident (Mitralign)
Direct annuloplasty
CE Mark trial
completed
US feasibility trial
planned
– Transcatheter annuloplasty for mitral repair
– Involves delivery of polyester pledgets via LV through posterior
mitral annulus
– Pledgets are plicated and locked directly on the annulus
Cardioband TF (Valtech)
Direct annuloplasty
CE Mark trial
underway
– An adjustable, sutureless posterior annuloplasty band implanted
trough transfemoral transeptal route
– Designed to reduce the septo-lateral annular diameter
Millipede Ring (Millipede)
Direct annuloplasty
Preclinicals underway Nitinol ring designed for tricuspid or mitral valve repair
Cardica Mitral Repair (Cardica)
Edge-to-edge repair
Intellectual property
developed
Catheter-based treatment for MR featuring a clip that holds together
the leaflets of the mitral valve
Continued
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the current state-of-the-art of mitral valve intervention, and to iden-
tify the potential future scenarios, which might benefit most from the
transcatheter repair and replacement devices under development.
Transcatheter mitral valve
implantation vs. repair: two
philosophies
Whereas mitral valve repair is currently the most widely used ap-
proach for transcatheter interventions for MR, TMVI offers several
theoretical advantages. Transcatheter mitral valve implantation is
potentially applicable to a greater proportion of patients; there is a
hope that TMVI could provide the concept of ‘one valve fits all’,
MR reduction may be more predictable, and the procedure may be
less technically demanding and easier to learn. However, due to pro-
cedural and design challenges to TMVI, complications may be more
catastrophic and less forgiving, while transcatheter mitral valve
repair (TMVRep) may be associated with a superior safety profile
as it involves a less marked change in valve anatomy and physiology.
Repair does not entail a heterologous tissue implant, the related sup-
porting structure does not require anti-coagulation, and it has been a
general conclusion in the surgical experience that repair has advan-
tages over valve replacement. The major limitation of TMVRep is
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Table 1 Continued
Device name and therapy
type
Device structure Status international Description
MISTRAL (Mitralix)
Chordal repair
Preclinicals underway – Transseptally delivered (12 Fr catheter) implant (3D Nitinol
spiral-shaped atraumatic wire) for mitral valve repair via chord
grasping
– This is Mitralix’s 1st product
V-Chordal-Transfemoral
(Valtech)
Chordal repair
Preclinicals underway – Transfemoral chord repair performed via transfemoral approach
that is off-pump on a beating heart
Kardium MR (Kardium)
Direct annuloplasty
Intellectual property
developed
– Kardium is developing a percutaneous device for treating mitral
valve regurgitation
PS3 (MVRx)
Annuloplasty
First-in-man study
underway
– Direct leveraged transatrial shortening of the septo-lateral
dimension of the mitral valve by providing two anchor points that
are tensioned together
MitraFlex (TransCardiac)
Edge-to-edge
Preclinicals underway – Instruments for minimally invasive transapical mitral valve repairs
ValCare MV Repair (ValCare)
Direct annuloplasty
Preclinicals underway – A rigid, ‘D-shape’ annuloplasty ring that is delivered in a
transcatheter approach to reduce MR and stabilize the mitral
annulus fur functional and degenerative MR
Mitra-Spacer-Transapical
(Cardiosolutions)
Enhanced coaptation
First-in-man study
underway
– Catheter-based mitral valve spacer to reduce MR improving
leaflet coaptation
– Implanted through transapical approach
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Table 2 Transcatheter mitral valve implantation technology under development
Device name Device structure Status
international
Description
Fortis (Edwards
Lifesciences)
First-in-man study
underway
– Mitral valve replacement technology designed to minimize
para-valvular leak
– Initial version being studied in first-in-man has a transapical delivery
system
Tiara (Neovasc) First-in-man study
underway
– Self-expanding bovine pericardial, D-shaped trileaflet mitral valve
implanted using a transapical delivery system
– It is anchored to the mitral annulus
– A transfemoral delivery system is also in development
TMVI-TA (CardiAQ) First-in-man study
completed
– Self-positioning, self-anchoring, and self-conforming system for
transcatheter mitral valve implantation through transapical approach
TMVI-TF (CardiAQ) First-in-man study
completed
– Self-positioning, self-anchoring, and self-conforming system for
transcatheter mitral valve implantation
– 2nd-generation device has been developed; this profile covers
transfemoral version
Caisson TMVR (Caisson) Preclinicals underway – Mitral valve replacement system with a transfemoral delivery system
MitraCath (Emory
University)
In development – Technology that enables the placement of a stent-mounted
bioprosthetic heart valve in the mitral position
HighLife Mitral Valve
Replacement (HighLife)
Preclinicals underway – Percutaneous mitral valve replacement technology with a transatrial
delivery system
Medtronic TMVR
(Medtronic)
Preclinicals underway – Self-expanding nitinol scaffold and a bovine pericardium valve with
three cusps
– Designed for fixation with the native mitral annulus
MitrAssist Valve
(MitrAssist)
Preclinicals underway – A mitral valve that fits into the existing mitral valve
– Delivered through a small-diameter catheter
– For all forms of mitral regurgitation
Navigate TMVR (NCSI) Clinical implants have
occurred
– Self-expandable mitral valve replacement device featuring a nitinol
stent and dehydrated tissue for treatment of functional mitral
regurgitation
– Transatrial, transapical, and transseptal versions are also in
development
Continued
F. Maisano et al.1654
that MR reduction is less predictable and MR may persist or reoccur.
Recurrence could be greater in FMR, due to further remodelling11
or to poor patient selection. In addition, operators may need to
master multiple transcatheter repair techniques to manage the
wide variability of mitral disease, and the need to combine different
devices in some patients to approximate a complete surgical repair
(Figures 1 and 2).
Given the advantages and disadvantages of these two approaches,
a patient-specific decision-making algorithm for the optimal device
choice will likely be required.
Mitral valve apparatus physiology:
the valve as an integrated
component of the left ventricle
The mitral valve is not simply just a valve, it is rather a complex appar-
atus integrated in the left ventricle (LV), including the annulus, the
leaflets, the chordae, the papillary muscles, and the ventricle itself.
Beyond its obvious haemodynamic function to ensure forward
cardiac output, the mitral apparatus plays a fundamental role in the
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Table 2 Continued
Device name Device structure Status
international
Description
Tendyne/Lutter TMVR
(Tendyne)
First-in-man study
underway
– Self-expanding, transapical approach to mitral valve replacement
– System involves neochords with left ventricular apical tethering for
fixation
Cardiovalve (Valtech) Preclinicals underway – Mitral valve replacement system that can be delivered using a
transfemoral delivery system in a two-step replacement procedure
Figure 1 Fluoroscopic and echocardiographic imaging guidance of transcatheter mitral repair procedures. Most transcatheter mitral repair pro-
cedures are technically demanding and require advanced integrated 3D echocardiographc guidance. (A, B, and C) The three-dimensional echocar-
diography, the fluoroscopic view, and the intercommissural two-dimensional echocardiography views of a direct annuloplasty procedure with the
Cardioband, respectively. (D, E, and F) Three-dimensional echocardiography, the fluoroscopic view, and two-dimensional colour-comparing echo-
cardiography views of during MitraClip implantation.
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structural and functional integrity of the LV. Discontinuation of the
mitral-ventricular continuity results in maladaptive remodelling and
impaired LV performance.12 In patients with FMR and severely
depressed LV function, contractility of the base of the LV is a key con-
tributor to cardiac output; as a consequence, in patients with pros-
thetic mitral valve, the fixation of the prosthesis to the annulus may
lead to a global reduction in contractility.13
The mitral valve plays a fundamental role in the demarcation of the
inflow–outflow ventricular tracts, and regulates the flow pattern
within the LV. Its fluid-dynamic function prevents energy loss and opti-
mizes fluid–structure interaction.14 The anterior leaflet of the mitral
valve acts as a rudder during the cardiac cycle to redirect flow
towards the outflow tract in systole and towards the lateral wall in dia-
stole,15 generating a virtuous fluid vortex.16 Loss of the vortex-like cir-
culation is associated with loss of energy, increased LV stress and less
efficient work.17–19 Preservation of anterior leaflet mobility and asym-
metric flow may be associated with better LV performance and may
partially explain the loss of ventricular function following replacement.
Mitral repair vs. replacement:
lessons learned from surgical
experience
A direct translation of the surgical experience to the transcatheter
procedures is not always appropriate; however, lessons learned
from .50 years of surgery should not be neglected in the develop-
ment of these new technologies.
Before extracorporeal circulation was available, several off-pump
mitral repair techniques were attempted. With the introduction of
cardiopulmonary bypass, an open-heart direct access approach and
the development of mechanical prostheses, early repair was used
progressively less often. Surgeons opted for valve replacement
because it was easier to perform and more predictable. Soon the
downsides of valve replacement became obvious: the need for
anti-coagulation, risk of thromboembolism, prosthetic endocarditis,
and impaired LV-function to name a few. Therefore, valve repair
re-emerged as the preferred surgical treatment for degenerative
MR (DMR) due to improved outcomes.20 –22
Incurrent surgicalpractice, replacement andrepair are complemen-
tary rather than competitive. According to guidelines, surgical repair
should be performed whenever feasible and early intervention is war-
ranted when durability is predicted.23,24 Conversely, valve replace-
ment may be considered as replacing one disease state (native valve
MR) with another (prosthesis), since the ideal prosthesis has not
been developed (Table 3). The advantages of repair over replacement
are more evident in patientswithDMR: in thesepatients timely surgical
repair restores life-expectancy and provides quality of life similar to an
age-matched general population,20,21 results that are not realized with
a prosthesis,25 even in elderly and high-risk patients.26,27
In this regard, although mitral valve repair may be more respectful
of the innatephysiology, and avoids prosthesis-related complications,
Figure2 Fluoroscopic and echocardiographic imaging guidance of transcatheter mitral valve implantation with the Fortis bioprosthesis (Edwards
Lifesciences). Whencompared with transcatheter mitral valve repair, reproducibilityof transcathetermitral valve implantation maybe higherand the
learning curve may be shorter. (A and B) Two steps of the Fortis valve deployment under fluoroscopic guidance; (C) The phase of leaflet capture at
bidimensional echocardiography; (D) The final implantation at three-dimensional echocardiography.
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careful patient selection (and operator experience) plays a key role in
achieving ideal initial and sustained outcomes.
Conversely, the benefits of surgical repair in patients with FMR are
less clear: in secondary MR prognosis is dominated by the underlying
LV dysfunction rather than the type of intervention.28,29 Surgical
replacement has traditionally been associated with higher early mor-
tality due to lessefficientpreservationof LV function.However, these
data arose from retrospective observational studies that were con-
founded by patient selection and other factors, including surgical ex-
pertise and technique.28,30,31 In a large multicentre randomized trial
comparing valve repair to chordal-sparing valve replacement in is-
chaemic FMR patients, Ackeret al.11 did not observe significant differ-
ences in LV reverse remodelling or survival at 1 year. Mitral valve
replacement compared with repair provided a more durable correc-
tion of MR, although this was not associated with a substantial differ-
ence in clinical outcomes. An important limitation of the trial is that
well established negative predictors for recurrence of MR after
repair in the setting of FMR were not acknowledged. This outcome
underlines the importance of patient selection to achieve durable
results after TMVRep in FMR.32,33 Although the study was not
powered for mortality, peri-operative mortality favoured repair
(1.6 vs. 4.0% 30-day mortality, P ¼ 0.26), consistent with a recent
meta-analysis comparing replacement and repair in patients with
ischaemic MR.34
Unsolved technical issues with
transcatheter mitral valve
implantation and transcatheter
mitral valve repair
From a pure technical standpoint, transcatheter repair and valve im-
plantation have distinct challenges and advantages (Table 4).
In patients with chronic MR, the annulus is usually dilated, requiring
large devices to obtain adequate fixation and sealing and large deliv-
ery systems, typically≥24F. Transfemoral retrograde and transseptal
(transfemoral or transjugular) approaches for TMVI delivery may be
challenging given the angulation involved and the dimensions and in-
flexibility of the devices. A direct transatrial approach is a possible al-
ternative.35 This approach, however, has been essentially abandoned
because of sub-optimal coaxial alignment. The transapical approach
assures optimal coaxial alignment; however, the LV wall in heart
failure patients with FMR is thin, and the LV dilated, dysfunctional,
and arrhythmogenic. Dedicated transapical closure devices are
under development and may facilitate TMVI. Finally, patients with se-
verely depressed LV systolic function may not tolerate prolonged de-
ployment time or rapid pacing impairing haemodynamic stability.
Stable anchorage of the prosthesis to prevent displacement or mi-
gration while enduring continuous cyclical movements of the mitral
annulus and the base of the LV as well as of the pressure gradients
between the left atrium and LV is of extreme importance. Reliable fix-
ation of the prosthesis is challenging; given the lack of heavy annular
calcification in most patients, fixation methods relying solely on
radial force are unlikely to be successful. Radial force also risks com-
pression and damage of adjacent structures such as the LV outflow
tract (LVOT), the conduction system, the coronary sinus, the left cir-
cumflex artery, and aortic root. Additional fixation elements are thus
required to ensure proper fixation to the LV or to other components
of the sub-valvular apparatus. Since para-valvular regurgitation may
be less tolerable in the mitral position, the design of the transcatheter
mitral prosthesis must aim at complete sealing.
The wide spectrum of anatomical variations underlying MR intro-
duces further challenges for prosthesis fixation, delivery and sealing:
not only are DMR and FMR anatomies different, but DMR includes a
Table 3 The ideal prosthetic valve
The (non-existing) ideal valve prosthesis
Simple and reproducible implant (high immediate success rate with
absent MR)
Absence of transvalvular gradient
Absence of peri-valvular regurgitation
No LVOT, coronary sinus, or LCX obstruction
Preservation of LV contractility, haemodynamics, and blood flow
pattern
Non-thrombogenic (no need for chronic anti-coagulation)
Low infection rates
No acute or delayed embolization
Durable
Ability to grow (in paediatric patients)
MR, mitral regurgitation; LVOT, left ventricle outflow tract; LCX, left circumflex
coronary artery; LV, left ventricle.
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Table 4 Comparison of transcatheter mitral valve
implantation and transcatheter mitral valve repair
TVMI TMVRep
Advantages
Simplicity More natural haemodynamics
Versatility No need for long-term
anti-coagulation
Predictable results Favourable safety profile
Challenges
Dynamic mitral structure Need for advanced imaging
Asymmetric anatomy Variability of disease/need for
multiple devices
Deliverability (profile, rigidity) Possible need for combined
therapies
Fixation (not relying on radial
force)
Steeper learning curve
Need for chronic oral
anti-coagulation (?)
Residual/recurrent regurgitation
Risk of LVOT, CS, and LCX
obstruction
Risk of para-valvular leak
TMVI, transcatheter mitral valve implantation; TMVRep, transcatheter mitral valve
repair; LVOT, left ventricle outflow tract; CS, coronary sinus; LCX, left circumflex
coronary artery.
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wide spectrum of pathological derangements, ranging from Barlow’s
disease (in which the extreme excess of tissue may prevent optimal
fixation) to fibroelastic deficiency with isolated segmental prolapse
(in which the lack of tissue may not assure an adequate landing
zone). The level of implantation and configuration of the bioprosth-
esis is crucial tominimize the riskof LVOTobstruction (with impaired
outflow fluid dynamics), and left atrial protrusion (with impaired
inflow fluid dynamics). The potential for erosion and device-related
thrombus formation have yet to be defined.
Transcatheter mitral valve repair has its own series of challenges.
Rarely, with current devices, TMVRep eliminates MR. The degree
of MR reduction to achieve a substantial clinical benefit is still
matter of concern, but it is obvious that the potential of TMVI for
complete and predictable abolition of MR is appealing. However, in
patients with FMR, a mild degree of residual MR after repair may miti-
gate the acute rise in overload and serve to decompress the LV,
making the procedure safer for those with severe LV dysfunction.
Further studies are necessary to examine this possibility.
Due to the wide anatomical variability of MR, physicians dedicated
to transcatheter mitral interventions will likely need to develop ex-
pertise with more than one device. Most TMVRep approaches will
require advanced imaging and specific skills,36,37 which may limit
their uptake, when compared with TVMI. Learning curve is longer
in repair, similar to surgery,38,39 and outcomes can be less predictable
in the early operator/centre experience.
These challenges are counterbalanced by an inclination of
TMVRep to be tolerable (as for MitraClip therapy), and associated
to fast recovery. This may be especially important in heart failure
patients with FMR.
Ultimately, it is most probably that, like with surgery, TMVRep and
TMVI will be both complementary and competitive.
Additional considerations:
durability and need for
anti-coagulation
Design constraints for transcatheter delivery may have an impact on
tissuedegenerationof TMVI.Durabilityof mitral tissueprostheses is a
concern in surgery, especially in younger patients.40,41 If transcath-
eter procedures aim to become a realistic alternative to surgery
with expanded indications to treat a lower risk population, durability
could become a major priority.
Durability is also an important issue forpercutaneous mitral repair.
In the EVEREST II trial, when acute procedural results were optimal,
repair with the MitraClip was durable for 5 years.42 However, with
sub-optimal MR repair or MR recurrence, patient outcomes are
poor.43 –47 In this regard, successful acute reduction of MR is neces-
sary to provide durable results of TMVRep, suggesting that patients
eligible for reconstructive procedures should be treated preferably
in experienced centres, similar as for mitral surgery.48
A second unknown issue is whether TMVI patients will need or
benefit from chronic anti-coagulation. Chronic anti-coagulation is
associated with increased risk of haemorrhagic and thrombotic
events.49,50 If chronic anti-coagulation is required, TMVI may be
less attractive for low-risk cohorts, if not otherwise indicated.
Safety is key for an ‘early indication’
with transcatheter mitral
procedures
Transcatheter mitral interventions are the natural evolution of
modern mitral valve surgery; in the future, the indications may con-
tinue to move from a palliative target (improving symptoms, treating
advanced and end-stage disease), towards the aim of improving prog-
nosis. Early repair can restore life expectancy in DMR patients and
lead to reverse remodelling in FMR patients.21,43,51 Outcomes tend
to be poor if mitral valve surgery is excessively delayed, and it is
likely that transcatheter mitral procedures may similarly be unable
to impact the prognosis if unduly postponed.52,53
In patients with severe MR and little or no symptoms, an excellent
safety profile is mandatory if early repair is to be considered. Under
these circumstances, like in surgery, a percutaneous repair may be
favoured over TMVI due to potential disadvantages of a permanent
implant. In this regard, there are numerous examples of therapies
where safety has a dominant role over efficacy. For example, cardiac
resynchronization therapy (CRT) in heart-failure patients is widely
accepted given its excellent safety record. Even if clinical efficacy is
achieved only in 60–70% of cases,54 patients are still referred for CRT
because the chance of improvement is associated with minimal risk.
Conclusions: The future of
transcatheter mitral interventions
At the moment, given the rapid evolution in device development, the
complementary role of TMVRep and TMVI must be considered
speculative. In general terms, TMVI is likely to be technically simpler
and more reproducible in terms of MR reduction. However, durability,
safety and disruption of adjacent cardiac structures remain important
concerns. Transcatheter mitral valve repair is more complex and
likely carries a steeper learning curve, and individual device may be
applicable only in selected patients with less predictable MR reduc-
tion. Of note, the safety profile of TMVRep is generally excellent,
and durability is likely to be robust in most patients when acute pro-
cedural success is achieved and the impact of TMVRep on physiology
is minimal. Therefore, TMVRep may in the future aspire to an early
treatment option, aiming at a prognostic approach, if randomized
trials can demonstrate equipoise in long-term outcomes when com-
pared with minimally invasive mitral valve repair.
In low-risk DMR patients, surgical repair will remain the standard
of care for many years, with TMVRep and TMVI playing a role in high-
risk or inoperable patients, who are not amenable for minimally inva-
sive surgical mitral valve repair or eventually for TMVRep.
In patients with severe FMR, the role of surgery is less well estab-
lished in patients who are not candidates for CABG, and most
patients are treated medically. Transcatheter mitral valve repair
may be a safe, palliative approach for such patients, and several
large-scale randomized ongoing trials investigate the effectiveness
of the MitraClip in this scenario. Transcatheter mitral valve implant-
ation may potentially be a therapeutic option for patients with more
advanced disease and severe anatomical and functional abnormal-
ities, who are not eligible for valve repair.
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In the future, carefulpatient selectionwill playa fundamental role in
identifying specific patients most likely to benefit from TMVI vs.
TMVRep vs. mitral valve surgery. Pre-procedural imaging will play a
leading role to guide the complex process of patient selection.
Some procedures may become complementary (i.e. surgical mitral
annuloplasty and subsequent TMVI, or a combination of different
TMVRep approaches in the same patients with staged procedures).
As an example, the addition of transcatheter annuloplasty to Mitra-
Clip therapy may improve acute efficacy and long-term durability.
However timing, indications and sequence of procedures is specula-
tive at the moment. Conversely, certain procedures may preclude
others (i.e. following TMVI there are no options for further repair,
and a transcatheter edge-to-edge repair may preclude future TMVI).
The role of LV remodelling approaches has yet to be defined.
The development of TMVRep techniques has already taken 15
years, and transcatheter valve implantation technology will likely
require more time until the devices and implant procedure are opti-
mized. In the meantime, there may be room for both surgery and
current TMVRep devices.
In the future, focus should be placed in designing and testing new
devices, improving imaging guidance, and then carefully evaluate
the risks and benefits of each promising approach in individual
patients in varying clinical settings, ultimately relying on randomized
trial evidence to guide clinical decision-making of the heart team.
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